I will be present at the High content Analysis and 3D Screening Conference in Boston from Monday (November 7) to Wednesday (November 9).
“Now in its fifteenth year, Cambridge Healthtech Institute’s High-Content Analysis & 3D Screening Conference will deliver the most recent developments in high-content and phenotypic screening. Leading pharma and academic researchers will focus on advancements in HCA technologies and applications, including screening of 3D and physiologically-relevant cellular models, data analysis techniques, and case studies and strategies for successful drug discovery. The expanded 3-day coverage on 3D cellular models and 3D screening will present the latest in spheroid, organoid and organotypic cell culture, and organ-on-a-chip technologies for drug screening, toxicity testing, and disease modeling.”
In this conference, I will present a poster on our collaborative work with Dr Karim Si-Tayeb, researcher from Institut du Thorax (CHOPIN project) on differentiation of iPS in hepatocytes in 3D culture for metabolic diseases screening.
If you want to know more on this project, don’t hesitate to come and discuss with me or contact us.
1 Comment
HCA conference 2017 in Boston : what we retain | HCS-pharma · November 23, 2017 at 2:52 pm
[…] were present at the last HCS conference in Boston and, during these two days of intensive discussions, lots of topics were addressed in HCS and HCA. […]